Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

Journal of Infectious Diseases

Volumn 204, Issue 5, 2011, Pages 753-760

  Spudich, Serena ^a   Gisslen, Magnus ^b   Hagberg, Lars ^b   Lee, Evelyn ^a   Liegler, Teri ^a   Brew, Bruce ^c   Fuchs, Dietmar ^d   Tambussi, Giuseppe ^e   Cinque, Paola ^e   Hecht, Frederick M ^a   Price, Richard W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; NEOPTERIN;

ADULT; ALBUMIN BLOOD LEVEL; ANALYTIC METHOD; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM FUNCTION; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DISEASE TRANSMISSION; EARLY DIAGNOSIS; ENCEPHALITIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSTIMULATION; LEUKOCYTE COUNT; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERODIAGNOSIS; VIRUS IMMUNITY; VIRUS LOAD;

ADULT; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; CHEMOKINE CCL2; CHEMOKINE CXCL10; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; LEUKOCYTE COUNT; MALE; NEOPTERIN; RNA, VIRAL; SERUM ALBUMIN; TIME FACTORS; VIRAL LOAD;

EID: 80051726729     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir387     Document Type: Article

References (49)

1. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986; 19:517-524 (Pubitemid 16085185)
2. Wong MH, Robertson K, Nakasujja N, et al. Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology 2007; 68:350-355 (Pubitemid 46184210)
3. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002; 8:136-142 (Pubitemid 34520894)
4. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004; 18:S75-S78 (Pubitemid 38365909)
5. Venturi G, Catucci M, Romano L, et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 2000; 181:740-745 (Pubitemid 30131851)
6. Davis LE,Hjelle BL,Miller VE, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992; 42:1736-1739
7. Enting RH, Prins JM, Jurriaans S, Brinkman K, Portegies P, Lange JM. Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection. Clin Infect Dis 2001; 32:1095-1099 (Pubitemid 32299646)
8. Pilcher CD, Shugars DC, Fiscus SA, et al. HIV in body fluids during primary HIV infection: Implications for pathogenesis, treatment and public health. AIDS 2001; 15:837-845 (Pubitemid 32424387)
9. Tambussi G, Gori A, Capiluppi B, et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis 2002; 30:962-965
10. Centlivre M, Sala M, Wain-Hobson S, Berkhout B. In HIV-1 pathogenesis the die is cast during primary infection. AIDS 2007; 21:1-11. (Pubitemid 44912531)
11. Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol 2006; 18:399-405. (Pubitemid 43947575)
12. Lindbäck S, Karlsson AC, Mittler J, et al. Karolinska Institutet Primary HIV Infection Study Group. Viral dynamics in primary HIV-1 infection. AIDS 2000; 14:2283-2291
13. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879 (Pubitemid 37070272)
14. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-264 (Pubitemid 126449269)
15. Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002; 16:1119-1129 (Pubitemid 34533850)
16. Carne CA, Tedder RS, Smith A, et al. Acute encephalopathy coincide with seroconversion for anti-HTLV-III. Lancet 1985; 326:1206-1208 (Pubitemid 16211793)
17. Ho DD, Rota TR, Schooley RT, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. New Engl J Med 1985; 313:1493-1497 (Pubitemid 16182477)
18. Denning DW. The neurological features of acute HIV infection. Biomed Pharmacother 1988; 42:11-14
19. Hagberg L, Malmvall BE, Svennerholm L, Alestig K, Norkrans G. Guillain-Barré syndrome as an early manifestation of HIV central nervous system infection. Scand J Infect Dis 1986; 18:591-592 (Pubitemid 17197959)
20. Piette AM, Tusseau F, Vignon D, et al. Acute neuropathy coincident with seroconversion for anti-LAV/HTLV-III. Lancet 1986; 1:852. (Pubitemid 16128965)
21. Brew BJ, Perdices M, Darveniza P, et al. The neurological features of early and 'latent' human immunodeficiency virus infection. Aust N Z J Med 1989; 19:700-705 (Pubitemid 20114756)
22. Scarpini E, Sacilotto G, Lazzarin A, Geremia L, Doronzo R, Scarlato G. Acute ataxia coincident with seroconversion for anti-HIV. J Neurol 1991; 238:356-357
23. Castellanos F, Mallada J, Ricart C, Zabala JA. Ataxic neuropathy associated with human immunodeficiency virus seroconversion. Arch Neurol 1994; 51:236. (Pubitemid 24088405)
24. Zetola NM, Pilcher CD. Diagnosis and management of acute HIV infection. Infect Dis Clin North Am 2007; 21:19-48, vii. (Pubitemid 46729635)
25. Lindbäck S, Thorstensson R, Karlsson AC, et al. Karolinska Institute Primary HIV Infection Study Group. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. AIDS 2000; 14:2333-2339
26. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82:5510-5518 (Pubitemid 351705258)
27. Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL)-A marker of active HIV-related neurodegeneration. J Neurol 2007; 254:1026-1032 (Pubitemid 47353414)
28. Spudich SS, Nilsson AC, Lollo ND, et al. Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005; 5:98.
29. Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis 2007; 195:1774-1778 (Pubitemid 46870250)
30. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286:171-179 (Pubitemid 32640848)
31. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526
32. Davenport MP, Zhang L, Shiver JW, Casmiro DR, Ribeiro RM, Perelson AS. Influence of peak viral load on the extent of CD4+ T-cell depletion in simian HIV infection. J Acquir Immune Defic Syndr 2006; 41:259-265
33. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004; 104:942-947 (Pubitemid 39038012)
34. Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006; 42:1333-1339
35. Wallace MR, Nelson JA, McCutchan JA, Wolfson T, Grant I. Symptomatic HIV seroconverting illness is associated with more rapid neurological impairment. Sex Transm Infect 2001; 77:199-201. (Pubitemid 32595743)
36. Ho DD, Sarngadharan MG, Resnick L, Dimarzoveronese F, Rota TR, Hirsch MS. Primary human T-lymphotropic virus type III infection. Ann Intern Med 1985; 103:880-883 (Pubitemid 16175498)
37. Chiodi F, Sönnerborg A, Albert J, et al. Human immunodeficiency virus infection of the brain. I. Virus isolation and detection of HIV specific antibodies in the cerebrospinal fluid of patients with varying clinical conditions. J Neurol Sci 1988; 85:245-257
38. Sönnerborg AB, von Stedingk LV, Hansson LO, Strannegå rd OO. Elevated neopterin and beta 2-microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS 1989; 3: 277-283 (Pubitemid 19167469)
39. Hagberg L, Dotevall L, Norkrans G, Larsson M, Wachter H, Fuchs D. Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis 1993; 168:1285-1288 (Pubitemid 23317152)
40. Cinque P, Bestetti A, Marenzi R, et al. Cerebrospinal fluid interferongamma- inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol 2005; 168:154-163 (Pubitemid 41396413)
41. González-Scarano F, Martín-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5:69-81. (Pubitemid 40070332)
42. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE. A coat of many colors: Neuroimmune crosstalk in human immunodeficiency virus infection. Neuron 2009; 64:133-145
43. Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferongamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 1991; 41:69-74.
44. Kolb SA, Sporer B, Lahrtz F, Koedel U, PfisterH, FontanaA. Identification of a T cell chemotactic factor in cerevrospinal fluid of HIV-1-infected individuals as interferon-c inducible protein 10. J Neuroimmunol 1999; 93:172-181 (Pubitemid 29051563)
45. Marra CM, Maxwell CL, Collier AC, Robertson KR, Imrie A. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis 2007; 7:37.
46. Sinclair E, Ronquillo R, Lollo N, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 2008; 47:544-552 (Pubitemid 351442007)
47. Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol 2010; 84:2395-2407
48. Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63:213-221 (Pubitemid 351355300)
49. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: Prevalence and risk factors. J Acquir Immune Defic Syndr 2007; 45:174-182 (Pubitemid 46869810)